Randomized Double--‐Blinded, Controlled Trial to Compare the Effectiveness of Sugammadex vs. Placebo to Prevent Residual Neuromuscular Block in the Post--‐Anesthesia Care Unit as Evaluated With a Non--‐Invasive Respiratory Volume Monitor
Phase of Trial: Phase IV
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 15 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 15 Aug 2017 Status changed from not yet recruiting to recruiting.
- 01 Jul 2016 Planned number of patients changed from 150 to 300.